Results 131 to 140 of about 406,491 (336)

The expression of APE1 in triple-negative breast cancer and its effect on drug sensitivity of olaparib

Tumor Biology, 2017
Triple-negative breast cancer is a kind of breast cancer with poor prognosis and special biological behavior, which lacked endocrine therapy and targeted therapy.
Tianran Chen, Chuan Liu, Heng Lu, Mingzhen Yin, Changjuan Shao, Xiaoding Hu, Jiaxue Wu, Yajie Wang   +7 more
doaj   +1 more source

Prevalence of Germline Mutations in Genes Engaged in DNA Damage Repair by Homologous Recombination in Patients with Triple-Negative and Hereditary Non-Triple-Negative Breast Cancers.

PLoS ONE, 2015
PurposeThis study sought to assess the prevalence of common germline mutations in several genes engaged in the repair of DNA double-strand break by homologous recombination in patients with triple-negative breast cancers and hereditary non-triple ...
Pawel Domagala, Anna Jakubowska, Katarzyna Jaworska-Bieniek, Katarzyna Kaczmarek, Katarzyna Durda, Agnieszka Kurlapska, Cezary Cybulski, Jan Lubinski   +7 more
doaj   +1 more source

Orbital Metastases from Breast Cancer with BRCA2 Mutation: A Case Report and Literature Review. [PDF]

, 2018
Breast cancer is the second leading cause of cancer-related deaths in women in the United States. Of these women, 5-10% have an inherited form of breast cancer with a mutation in a major gene, such as the breast cancer susceptibility genes 1 or 2 (BRCA1 ...
Barber, Emily, Lane, Karen, Lin, Erin, Lyou, Yung, Mehta, Rita, Parajuli, Ritesh   +5 more
core   +2 more sources

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Annals of Oncology, 2019
BACKGROUND Treatment options for previously treated metastatic triple-negative breast cancer (mTNBC) are limited. In cohort A of the phase II KEYNOTE-086 study, we evaluated pembrolizumab as second or later line of treatment for patients with mTNBC ...
S. Adams, P. Schmid, H. Rugo, Eric P. Winer, D. Loirat, A. Awada, D. Cescon, H. Iwata, M. Campone, R. Nanda, R. Hui, G. Curigliano, G. Curigliano, D. Toppmeyer, J. O’Shaughnessy, J. O’Shaughnessy, S. Loi, S. Paluch-Shimon, A. Tan, D. Card, J. Zhao, V. Karantza, J. Cortés   +22 more
semanticscholar   +1 more source

Applicability of mitotic figure counting by deep learning: a development and pan‐cancer validation study

FEBS Open Bio, EarlyView.
In this study, we developed a deep learning method for mitotic figure counting in H&E‐stained whole‐slide images and evaluated its prognostic impact in 13 external validation cohorts from seven different cancer types. Patients with more mitotic figures per mm2 had significantly worse patient outcome in all the studied cancer types except colorectal ...
Joakim Kalsnes, Maria X. Isaksen, Frida Julbø, Manohar Pradhan, Andreas Kleppe, Sepp De Raedt, Ole‐Johan Skrede, Turid Torheim, John Arne Nesheim, Hans Martin Mohn, Hanne A. Askautrud, Karolina Cyll, Wanja Kildal, Emma Rewcastle, Melinda Lillesand, Vebjørn Kvikstad, Emiel Janssen, Robert Jones, Odd Terje Brustugun, Bjørn Brennhovd, Erik Skaaheim Haug, Lill‐Tove Rasmussen Busund, Elin Richardsen, Sigve Andersen, Tom Dønnem, Kristina Lindemann, Gunnar Kristensen, Neil A. Shepherd, Marco Novelli, Knut Liestøl, David Kerr, Håvard E. Danielsen, Tarjei S. Hveem   +32 more
wiley   +1 more source

New FTY720-docetaxel nanoparticle therapy overcomes FTY720-induced lymphopenia and inhibits metastatic breast tumour growth [PDF]

, 2017
Purpose: Combining molecular therapies with chemotherapy may offer an improved clinical outcome for chemoresistant tumours. Sphingosine-1-phosphate (S1P) receptor antagonist and sphingosine kinase 1 (SK1) inhibitor FTY720 (FTY) has promising anticancer ...
A Jemal, A Panariti, AS Paraskar, AV Korotcov, C White, Colin Cooper, D Pchejetski, D Pchejetski, D Pchejetski, D Pchejetski, D Simberg, Dmitri Pchejetski, E Fröhlich, F Yuan, FJ Esteva, H Alshaker, H Alshaker, H Alshaker, H Alshaker, H Azuma, H Gao, Heba Alshaker, HS Rugo, J Ohotski, JA Cohen, JM Nabholtz, K Adachi, K Maruyama, KJ French, L Kappos, L Sauer, L Treuel, M Noori Koopaei, MJ Ernsting, ML Immordino, N Kamaly, NJ Pyne, NK Ibrahim, P Kallinteri, P Parhi, P Yousefpour, Q Gu, Qi Wang, R Misra, R Rosa, S Basu, S Mitragotri, S Permpongkosol, S Saremi, Shyam Srivats, W Tao, WJ Gradishar, Y Li, Y Mousseau, Y Zong, Yimin Chao, ZH Mirzaie   +56 more
core   +1 more source

Exon 7 splicing of ERα predicts poor prognosis and increases phenotypic heterogeneity in luminal a subtype breast cancer

FEBS Open Bio, EarlyView.
ERα splice variant ERα∆7 lacks the C‐terminus, and its expression may change phenotypes of breast cancers. Our results showed that ERα∆7 is found in the luminal A subtype, and elevated ERα∆7 levels are linked to improved cell survival with lower proliferation and migration.
Long Wai Tsui, Taobo Hu, Thomson Christian Husein, Wai Hei Shek, Bingrong Chen, Depeng Wang, Shu Wang, Weichuan Yu, Xiaodan Fan, Mengping Long, Toyotaka Ishibashi   +10 more
wiley   +1 more source

Evaluation of Gene Expression Data From Cybrids and Tumours Highlights Elevated -Driven Proliferation in Triple-Negative Breast Cancer

Breast Cancer: Basic and Clinical Research, 2020
Background: Triple-negative breast cancer is an aggressive type of breast cancer with high risk of recurrence. It is still poorly understood and lacks any targeted therapy, which makes it difficult to treat.
Akanksha Mishra, Maria Bonello, Adam Byron, Simon P Langdon, Andrew H Sims   +4 more
doaj   +1 more source

Preclinical Analysis of JAA-F11, a Specific Anti-Thomsen-Friedenreich Antibody via Immunohistochemistry and In Vivo Imaging. [PDF]

, 2018
The tumor specificity of JAA-F11, a novel monoclonal antibody specific for the Thomsen-Friedenreich cancer antigen (TF-Ag-alpha linked), has been comprehensively studied by in vitro immunohistochemical (IHC) staining of human tumor and normal tissue ...
Adams, Julia, Fisk, John C, Ghazal, Diala, Jessee, Joseph, Johnson, Holly, Karacosta, Loukia G, Koury, Steven, Ludwig, Rachel, Olson, James R, Rittenhouse-Olson, Kate, Roy, Rene, Sajjad, Munawwar, Tati, Swetha, Turner, Bradley   +13 more
core   +2 more sources

Suppression of lung adenocarcinoma migration through organelle alkalization by human lactoferrin – albumin fusion

FEBS Open Bio, EarlyView.
This paper reveals how human lactoferrin–albumin fusion (hLF‐HSA) potently suppresses lung adenocarcinoma cell migration. hLF‐HSA upregulates NHE7, leading to Golgi alkalization, disruption of the Golgi secretome, downregulation of MMP1, and reversal of EMT. These findings suggest a novel Golgi‐targeting strategy to suppress cancer cell migration.
Hana Nopia, Masahiro Kimura, Daisuke Kurimoto, Atsushi Sato   +3 more
wiley   +1 more source